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It	 is	 known	 that	 chemoresistance	of	 tumors	 is	
among	 the	major	 problems	 of	modern	 oncology	
because	 it	 leads	 to	 failure	of	 therapy.	That’s	why	 it	
is	necessary	to	find	the	way	to	overcome	drug	resis-
tance.	The	related	approach	is	to	study	the	sensitivity	
of	 resistant	 tumors	 to	 the	action	of	 immunological	
mechanisms	of	antitumor	defense	[1].
Among	known	 types	of	 immunotherapy	 (therapy	
with	 the	use	of	monoclonal	antibodies,	cancer	vac-
cines,	 cytokines,	 adoptive	 immunotherapy	 etc)	
adoptive	immunotherapy	with	the	use	of	lymphocytes	
activated	with	 cytokines	occupies	a	 special	 place	
[2–5].	However,	the	data	on	its	use	for	the	treatment	
of	chemoresistant	tumors	are	limited,	and	mostly	they	
are	obtained	in	vitro	evidencing	on	a	pronounced	sen-
sitivity	of	the	cells	of	resistant	tumors	to	the	action	of	
LAK	[6–9].	The	data	on	the	use	of	vaccine	therapy	or	
combined	therapy	(vaccine	+	LAK)	of	chemoresistant	
tumors	are	nearly	absent.	There	is	some	positive	expe-
rience	on	the	combined	use	of	LAK-therapy	with	other	
types	of	immunotherapy	and	chemotherapy	[10,	11].	
As	we	have	shown	earlier,	chemoresistant	human	
tumors	 (soft	 tissue	sarcoma,	epithelial	 tumors)	and	
doxorubicin-resistant	animal	tumors	(В16	melanoma,	
transplantable	murine	MC-rhabdomyosarcoma)	de-
monstrated	elevated	sensitivity	 to	 the	action	of	LAK	
both	in vitro	and	in vivo	[12,	13].
At	the	same	time	it	remains	unknown	what	is	the	
sensitivity	of	chemoresistant	tumors	to	other	types	of	
immunotherapy,	in	particular,	to	vaccination	with	the	
use	of	cancer	vaccines	prepared	on	the	base	of	dif-
ferent	tumor	antigens.	The	different	technologies	for	
preparation	of	such	vaccines	are	used,	in	particular,	
the	vaccines	prepared	on	the	base	glycopeptide	car-
bohydrate	antigens	[14–17].	
The	aim	of	the	present	work	was	to	evaluate	the	effi-
cacy	of	different	types	of	immunotherapy	(LAK-therapy,	
vaccine	therapy	and	their	combination)	toward	doxoru-
bicin	(Dox)-sensitive	and	Dox-resistant	transplantable	
murine	MC-rhabdomyosarcoma (MC-RMS).
MATERIALS AND METHODS
In	the	study,	BALB/c	mice	weighting	15–20	g	bred	
in	 the	vivarium	of	R.E.	Kavetsky	 Institute	of	Experi-
mental	Pathology,	Oncology	and	Radiobiology,	NAS	
of	Ukraine	(Kyiv,	Ukraine)	were	used.	As	experimental	
tumor	models,	we	have	used	the	strains	generated	by	
us:	1)	Dox-resistant	MC-RMS	cells;	2)	Dox-sensitive	
MC-RMS	cells.
Lymphokin-activated	cells	(LAK)	were	obtained	by	
incubation	of	lymphocytes	from	lymph	nodes	of	tumor-
bearing	mice	(n	=	30)	with	recombinant	IL-2	(3	x	106	
cells	with	1000	МU	IL-2)	for	2	h	at	37	°С;	lymphocytes	
were	isolated	from	syngeneic	tumor-bearing	mice	at	
the	days	7–11	after	tumor	transplantation	accounting	
the	level	of	expression	of	IL-2	receptor	(CD25),	ana-
lyzed	by	the	method	of	indirect	immunofluorescence.	
LAK-therapy	was	performed	starting	from	day	7	after	
tumor	cell	transplantation	(at	the	stage	of	appearance	
of	tumor	node)	for	5	days;	LAK	(3	x	106	cells	in	0.2	ml	
of	medium)	were	injected	in	the	region	of	tumor.
For	vaccination,	an	autovaccine	prepared	by	 the	
method	of	controlled	proteolytic	hydrolysis	of	 tumor	
tissue	by	 its	treatment	with	the	filtrate	of	culture	me-
dium	of	Bacillus	subtilis	with	the	next	fractionation	by	
DEAE-chromatography	and	purification	of	polypeptides	
that	carry	polysaccharide	residues.	Determination	of	
polysaccharide	component	was	done	using	electro-
phoresis	in	polyacrylamide	gel.	Immunogenicity	of	the	
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vaccine	was	expressed	in	relative	units	equivalent	to	the	
number	of	tumor	cells.	The	technology	of	preparation	
of	glycopeptide	vaccine	is	patented	in	Ukraine,	and	it	is	
allowed	for	trials	[18].	Earlier,	the	efficacy	of	this	vaccine	
has	been	evaluated	in	other	in vivo	models	[19].
The	vaccine	was	administered	intraperitoneally	at	
the	volume	of	0.2	ml	by	two	different	schemes:	1)	vac-
cination	prior	to	tumor	transplantation	(triple	injection	
with	5	days	intervals);	tumor	was	transplanted	3	days	
after	the	last	injection;	2)	vaccination	at	the	day	7	after	
tumor	 transplantation	—	 triple	 injection	with	5	days	
intervals.	
Animals	bearing	 resistant	 and	sensitive	 tumors	
were	housed	in	the	next	groups	(20	animals	per	group)	
according	to	applied	therapy:	1)	adoptive	LAK-therapy;	
2)	 vaccine	 therapy;	 3)	 combined	 immunotherapy	
(adoptive	LAK-therapy	and	vaccine	therapy);	4)	control	
group	 (no	 therapy).	All	 researches	on	animals	were	
carried	out	in	accordance	with	Bioethic	standards	for	
study	on	animals	approved	in	Ukraine.
RESuLTS AND DIScuSSION
The	study	was	initiated	from	the	search	for	optimal	
scheme	and	dose	of	 vaccine	because	 this	 vaccine	
was	not	tested	in	MC-RMS	model.	The	efficacy	of	3	do-
ses	—	5000,	50	000	and	100	000	relative	units	(r.	u.	are	
equivalent	to	the	number	of	tumor	cells	used	for	vaccine	
preparation)	administered	at	two	regimens	mentioned	
above	was	studied.	We	have	shown	that	for	treatment	
of	MC-RMS,	the	optimal	dose	is	50	000	r.	u.	and	pro-
phylactic	scheme	of	vaccination,	and	exactly	this	dose	
and	scheme	of	vaccination	were	used	in	present	study;	
the	percent	of	tumor	growth	inhibition,	tumor	volume	
and	life	span	of	enimals	served	as	the	main	indexes	for	
evaluation	of	the	efficacy	of	the	therapy	[20].
For	Dox-sensitive	MC-RMS,	we	have	shown	that	
all	applied	types	of	immunotherapy	were	effective.	At	
the	day	9	after	 tumor	transplantation,	 tumor	growth	
inhibition	differs	significantly	in	all	immunized	animals	
compared	to	the	control,	but	not	in	mice	that	received	
LAK-therapy.	 In	 vaccinated	animals,	 the	percent	of	
tumor	growth	 inhibition	reached	its	maximum	at	the	
day	14	after	 tumor	 transplantation	and	was	62.9	±	
0.62%	versus	36.5	±	1.37%	(р	<	0.01)	for	LAK-therapy	
and	51.6	±	0.76%	(р	<	0.001)	in	the	case	of	combined	
therapy	(Fig.	1).	
fig. 1. Inhibition	of	 tumor	growth	 in	BALB/c	mice	bearing	
Dox-sensitive	MC-RMS	upon	the	influence	of	different	types	of	
immunotherapy
Analysis	of	average	 life	span	 (Fig.	2)	of	animals	
bearing	Dox-sensitive	 tumors	 also	 demonstrated	
significant	 benefit	 of	 vaccination	 compared	 to	
LAK-therapy	and	combined	therapy.
fig. 2. Life	span	of	BALB/c	mice	bearing	Dox-sensitive	MC-RMS	
upon	the	influence	of	different	types	of	immunotherapy
So,	vaccine	therapy	was	more	effective	for	treat-
ment	of	animals	bearing	Dox-sensitive	MC-RMS	than	
LAK-	and	combined	therapy.
Analogous	studies	were	carried	out	on	Dox-resis-
tant	MC-RMS	model,	and	 it	has	been	 revealed	 that	
upon	use	of	all	mentioned	types	of	 immunotherapy,	
significant	 increase	of	 the	percent	of	 tumor	growth	
inhibition	was	observed	in	animals	from	all	groups	with-
out	significant	differences	till	the	day	21	after	tumor	
transplantation	(57–60%).	However,	starting	from	the	
days	22–23,	LAK-therapy	was	found	to	be	more	effec-
tive	than	vaccine	therapy	or	combined	therapy;	At	the	
day	23,	28,	30	after	tumor	transplantation	in	animals	
that	received	LAK-therapy,	the	percent	of	tumor	growth	
inhibition	was	61.4	±	1.84%;	70.3	±	4.94%;	66.2	±	
6.24%	versus	48.8	±	3.85%	(р	<	0.001);	47.6	±	8.91%	
(р	<	0.05);	31.8	±	15.91%	(р	<	0.05)	for	vaccinated	
animals,	and	41.2	±	3.74%	(р	<	0.001);	42.6	±	8.71%	
(р	<	0.001);	45.7	±	10.33%	(р	<	0.1)	in	animals	that	
received	combined	therapy	respectively	(Fig.	3).
fig. 3. Inhibition	of	 tumor	growth	 in	BALB/c	mice	bearing	
Dox-resistant	MC-RMS	upon	the	influence	of	different	types	of	
immunotherapy
LAK-therapy	was	shown	to	be	more	effective	than	
vaccination	and	combined	therapy	also	by	the	index	
of	life	span	of	experimental	animals:	whilst	average	life	
span	in	control	group	was	32	days,	animals	treated	by	
LAK	survived	up	to	46–49	days	(Fig.	4).
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fig. 4. Life	span	of	BALB/c	mice	bearing	Dox-resistant	MC-RMS	
upon	the	influence	of	diffent	types	of	immunotherapy
So,	one	may	conclude	that	LAK-therapy	is	the	most	
effective	type	of	treatment	of	mice	bearing	Dox-resis-
tant	MC-RMS.	
Finally,	we	have	performed	comparative	analysis	
of	the	efficacy	of	different	types	of	immunotherapy	in	
mice	bearing	Dox-sensitive	and	Dox-resistant	MC-RMS	
(Fig.	5).	Firstly,	all	 types	of	 therapy	were	 found	to	be	
more	effective	 for	 treatment	of	Dox-resistant	 tumor.	
Secondly,	for	Dox-sensitive	tumor,	vaccine	therapy	was	
the	most	effective,	whilst	in	the	case	of	Dox-resistant	
tumor	adoptive	LAK-therapy	resulted	in	the	highest	life	
span	of	animals	and	highest	tumor	growth	inhibition.	
Thirdly,	 the	combined	 therapy	 in	 the	cases	of	both	
resistant	and	sensitive	tumors	occupies	intermediate	
place	between	vaccination	and	LAK-therapy.	
fig. 5. Comparative	analysis	of	the	efficacy	of	different	types	
of	 immunotherapy	 for	 treatment	 of	 BALB/c	mice	 bearing	
Dox-sensitive	and	Dox-resistant	MC-RMS
The	discussion	of	the	presented	results	is	compli-
cated	by	the	lack	of	information	on	the	mechanisms	of	
the	development	of	drug	resistance,	on	phenomenon	
of	elevated	sensitivity	of	chemoresistant	tumors	to	the	
action	of	immune	system,	but	there	is	an	opinion	that	
in	 these	processes	different	surface	molecules	ex-
pressed	on	tumor	cells	may	be	involved.	In	particular,	it	
was	reported	that	the	development	of	drug	resistance	
is	associated	with	expression	of	survivin	—	protein	that	
inhibits	apoptosis.	Survivin	was	found	on	the	cells	of	a	
number	of	tumors	(lung,	stomach,	mammary	gland,	
liver,	neuroblastoma),	and	its	high	level	of	expression	
correlates	with	 tumor	progression	 [21,	22].	 It	was	
shown	 that	surviving	 is	 involved	 in	 the	 formation	of	
radio-	and	chemoresistance	via	direct	or	mediated	
inhibition	of	caspases	[21].	
There	are	data	showing	 that	 the	development	of	
acquired	 resistance	 (in	particular,	 to	paklitaxel)	 in	
ovarian	carcinoma	cells	 is	associated	with	expres-
sion	of	Bub	R1	—	protein	that	belongs	to	the	family	
of	proteins	веретена	скручивания	[23].	The	study	of	
antiapoptotic	molecules	by	chemoresistant	tumor	cells	
is	in	spite	of	interest	too:	in	resistant	bladder	cancer	
cells,	elevation	of	Bcl-2	expression	upon	inhibition	of	
Bax	translocation	has	been	demonstrated	[24].	
At	 the	same	 time,	P-gp	—	 the	product	of	mdr1	
gene,	is	in	the	focus	of	studies.	It	was	shown	that	upon	
the	influence	of	chemopreparations,	there	are	altera-
tions	 in	epigenetic	modification	of	mdr	1	 locus	and	
methylation	of	promoter	of	mdr	1,	that	is	accompanied	
by	the	development	of	drug	resistance	[25].	
As	it	is	known,	P-gp	protein	may	play	physiologic	
role	as	well:	 it	 is	expressed	by	a	number	of	normal	
cells	(intestinal	epithelium,	some	hepatic	cells,	renal	
канальцев	etc)	where	 it	 plays	a	 correcting	 role	 in	
organogenesis	[26].	Moreover,	P-gp	is	expressed	in	
natural	killer	cells,	dendrite	cells,	Т-	and	В-lympho-
cytes,	but	its	role	in	these	cells	remains	unknown	[26].	
In	some	studies	the	authors	tried	to	analyze	whether	
expression	of	P-gp	correlates	with	elevated	sensitivity	
of	resistant	tumor	cells	to	effectors	of	immune	system	
[1],	but	till	now	no	significant	correlation	was	found.	
Analyzing	the	data	on	the	role	of	P-gp	in	the	develop-
ment	of	drug	resistance,	one	may	conclude	that	P-gp	is	
not	universal	protein	associated	with	chemoresistance	
(it	is	not	expressed	in	all	tumor	cells),	and	it	could	not	
block	completely	 apoptotic	mechanisms	 in	 tumor	
cells,	because	P-gp	blocks	only	caspase-dependent	
apoptosis,	whilst	ability	of	cells	to	undergo	caspase-
independent	apoptosis	is	restored	as	well	as	their	lysis	
by	cytotoxic	T-lymphocytes	with	 the	 involvement	of	
granzim	В	and	perforin	[27–29].	
It	is	necessary	to	discuss	why	our	data	showed	that	
for	therapy	of	Dox-resistant	tumors	LAK-therapy	is	the	
most	effective,	and	Dox-sensitive	MC-RMS-vaccine	
therapy.	Taking	into	account	that	the	mechanisms	of	
antitumor	action	for	mentioned	types	of	therapy	are	
principally	different	 [30,	31],	 it	 could	be	proposed	
that	in	animals	with	resistant	tumors	there	could	oc-
cur	changes	of	immune	system	that	affect	vaccination	
efficacy.	It	was	shown	that	upon	the	development	of	
drug	 resistance	 in	Dox-resistant	human	melanoma	
cells	(the	cells	did	not	express	P-gp)	cocultivated	with	
allogeneic	cells	of	peripheral	blood,	the	production	of	
IFN-γ	 in	the	latest	decreased	as	well	as	proliferation	
rate;	the	authors	supposed	that	this	phenomenon	may	
occur	in vivo	as	well	[32].	
In	experiments	with	L1210	cells	resistant	to	cyspla-
tin	 it	was	shown	that	the	expression	of	class	II	MHC	
antigens	decreased	on	their	surface	[33].	So,	upon	
formation	of	the	resistance	the	events	impeding the	
recognition	with	the	involvement	of	class	II	MHC	mol-
ecules	may	take	place,	when	this	process	occupies	
the	central	place	in	the	induction	of	immune	response	
upon	vaccination.	
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There	is	different	situation	upon	LAK-therapy:	the	
lysis	of	tumor	cells	is	performed	by	cytotoxic	cells	ac-
tivated	by	IL-2	in vitro,	where	expression	of	adhesion	
molecules	by	LAK	and	increase	of	cytokine	production	
is	of	special	importance.	Not	only	IL-2	possesses	such	
ability,	but	other	cytokines	as	well	in	particular	IL-12,	
IL-15,	IL-18	etc.	[1,	34–36].	That’s	why	LAK-therapy	
does	not	require	active	 involvement	of	 immunologic	
mechanisms	of	the	host	and	is	mainly	dependent	on	
the	patterns	of	 interacting	 lymphocytes	and	 tumor	
cells,	especially	expression	of	adhesion	molecules,	
significantly	affecting	the	efficacy	of	LAK-therapy.	For	
chemoresistant	 tumors	 this	problem	 is	not	 studied	
in vivo	yet;	it	was	shown	that	elevated	expression	of	
ICAM-1	by	 tumor	cells	 leads	 to	promotion	of	 their	
lysis	by	natural	killers	[34].	It’s	necessary	to	add	that	
adoptive	transfer	even	of	non-activated	cytotoxic	cells	
may	lead	to	the	lysis	of	resistant	tumor	cells	by	diffe-
rent	ways	[37].	The	study	of	molecular	mechanisms	
of	interaction	between	lymphocytes	and	tumor	cells	
will	 allow	understand	 the	phenomenon	of	elevated	
sensitivity	of	resistant	tumors	to	immunotherapy.
In	conclusion,	our	data	evidence	on	higher	efficacy	
of	all	applied	 types	of	 immunotherapy	 toward	 treat-
ment	of	mice	bearing	resistant	tumors	than	sensitive	
ones.	Comparative	analysis	of	the	efficacy	of	all	types	
of	 therapy	has	 shown	 that	 in	 the	case	of	 resistant	
tumors,	LAK-therapy	using	autologous	lymphocytes	
has	the	highest	efficacy,	when	in	the	case	of	sensitive	
tumors	vaccine	therapy	is	of	higher	efficacy.	
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Эффективность различных видов иммунотерапии 
по отношению к резистентной и чувствительной 
к доксорубицину перевивной мх-рабдомиосаркоме
Цель: изучить влияние различных видов иммунотерапии, а именно адоптивной ЛАК-терапии, вакцинотерапии, а также 
их комбинации, дать оценку их эффективности в условиях перевивной МХ-рабдомиосаркомы мышей, резистентной и 
чувствительной к доксорубицину. Материалы и методы: исследования проведены на мышах линии BALB/c с чувствительной 
и резистентной к доксорубицину перевивной МХ-рабдомиосаркомой. ЛАК-терапию (лимфоцитами лимфатических узлов 
сингенных мышей) проводили начиная с 7 сут после перевивки опухолевых клеток на протяжении 5 дней; ЛАК вводили в 
область опухоли в количестве 3 млн в 0,2 мл среды. Вакцину, полученную на основе гликопептидов опухолевых клеток, 
вводили мышам интраперитонеально в объеме 0,2 мл по двум схемам: до перевивки и после перевивки опухоли. Влияние 
иммунотерапии оценивали по проценту торможения роста опухоли и выживаемости животных. Результаты: данные 
проведенной иммунотерапии свидетельствуют, что у мышей с чувствительной к доксорубицину опухолью наиболее 
эффективна вакцинотерапия, а при резистентной опухоли — адоптивная ЛАК-терапия, что подтверждалось наибольшей 
протяженностью жизни и наиболее выраженным торможением роста опухоли у животных этой группы. Кроме того, 
сравнительный анализ результатов применения ЛАК-терапии, вакцинотерапии и их сочетания показал, что все ее виды 
эффективны у мышей как с чувствительной, так и резистентной к доксорубицину МХ-рабдомиосаркомой. Выводы: 
полученные данные свидетельствуют о том, что резистентные и чувствительные к доксорубицину опухоли отличаются 
чувствительностью к различным видам иммунотерапии, что, по всей вероятности, объясняется различными механизмами 
их действия.
Ключевые слова: перевивная МХ-рабдомиосаркома, резистентность, доксорубицин, вакцинотерапия, ЛАК-терапия.
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